MedTrace Logo

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

NCT06795022 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2026-04-06

No results posted yet for this study

Summary

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.

Conditions

Interventions

DRUG

AZD9793 Intravenous (IV) monotherapy

T cell-engaging antibody that targets GPC3 on tumour cells

DRUG

AZD9793 Subcutaneous (SC) monotherapy

T cell-engaging antibody that targets GPC3 on tumour cells

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-27
Primary Completion
2028-02-25
Completion
2028-07-25
FDA Drug
Yes

Countries

  • United States
  • China
  • Hong Kong
  • Japan
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06795022 on ClinicalTrials.gov